Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONX vs ABUS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABUS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

ABUS Overall Winner 6-Pillar Tally: IONX 0 – 6 ABUS Matrix Metrics: IONX 0 – 10 ABUS

As of Nov 16, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Defiance Daily Target 2X Long IONQ ETF (IONX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONX carries a Unified Composite Score of 48.8/100 (HOLD) at $8.27 (N/M Forward P/E, N/A operating margin), whereas ABUS carries 56.3/100 (HOLD) at $4.04 (10.2x Forward P/E, 80.1% operating margin).

  • Technical & Structure Timing Caution: IONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile ABUS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONX vs ABUS
IONX NASDAQ
Defiance Daily Target 2X Long IONQ ETF
Institutional Equity
$8.27
-16.55% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 6.79β · 232% Vol
Unified Composite Score
48.8 / 100 HOLD
Tech 45.0 Fund 51.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -24.5%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $12.36 · SMA50: $18.40
ABUS NASDAQ Head-to-Head Winner
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.04
-1.22% 1D
Market Cap $627.0M
TTM Revenue $181M
Forward P/E 10.2x
Beta / 30D Vol 1.20β · 51% Vol
Unified Composite Score
56.3 / 100 HOLD
Tech 72.0 Fund 65.0 Flow 68.0 Mom 53.7
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $4.05 · SMA50: $4.44

6-Pillar Scorecard Institutional Category Breakdown (IONX 0 – 6 ABUS)

Columns: Metric · IONX · ABUS
1. Valuation Multiples ABUS
Forward P/E N/M 10.2x
Trailing P/E N/M 3.6x
PEG Ratio N/M N/M
EV / Revenue N/M 2.0x
2. Growth & Scale ABUS
Revenue Growth (YoY) N/A -43.5%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $181M
Market Cap N/A $627.0M
3. Profitability & Quality ABUS
Gross Margin N/A 91.9%
Operating Margin N/A 80.1%
Net Profit Margin N/A 121.2%
Return on Equity (ROE) N/A 269.6%
4. Balance Sheet & Cash Flow ABUS
Cash Generation (TTM) N/A $221M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $264M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABUS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 181.8% (4th %ile) 72.9% (28th %ile)
Put/Call OI Skew N/A 0.18x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat ABUS
OpEx & R&D Intensity N/A 11.8% of Rev ($21M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONX (0) vs ABUS (10)
Institutional Metric IONX ABUS Criterion Row Edge
Market Capitalization
Scale
N/A $627.0M Larger Scale ABUS
Trailing P/E Ratio
Valuation
N/M 3.6x Lower Multiple ABUS
Forward P/E Ratio
Valuation
N/M 10.2x Lower Multiple ABUS
Revenue Growth (YoY)
Growth
N/A -43.5% Higher Growth ABUS
Operating Margin (TTM)
Profitability
N/A 80.1% Higher Margin ABUS
Net Profit Margin
Profitability
N/A 121.2% Higher Margin ABUS
Return on Equity (ROE)
Capital Efficiency
N/A 269.6% Higher ROE ABUS
52-Week Range Position
Momentum
0% ($8–$108) 28% ($4–$5) Stronger Trend ABUS
Beta / 30D Volatility
Risk Regime
6.79β · 232% Vol 1.20β · 51% Vol Lower Realized Risk ABUS
Unified Institutional Score
Composite Signal
48.8 / 100 (HOLD) 56.3 / 100 (HOLD) Higher Composite ABUS
Trailing 12M Revenue (USD)
Operating Scale
N/A $181M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 91.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $221M ($264M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABUS +32.55 pp
IONX: -36.82% · ABUS: -4.27%
3M Horizon ABUS +56.19 pp
IONX: -72.72% · ABUS: -16.53%
6M Horizon ABUS +80.63 pp
IONX: -83.75% · ABUS: -3.12%
1Y Horizon ABUS +73.11 pp
IONX: -84.51% · ABUS: -11.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IONX vs ABUS. Trailing 12-month operating profitability (IONX N/A vs ABUS 80.1%) and valuation multiples (IONX N/M vs ABUS 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.

IONX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$181M
Gross Margin91.9%
Op. Margin80.1%
ROE / Fwd P/E269.6% · 10.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 181.8%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IONX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABUS CONSOLIDATION
92d in phase · OBV ACCUMULATION
Current IV 72.9%
IV Percentile 28th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact ABUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABUS Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $627.0M market capitalization and 80.1% operating margin.
OpEx & R&D Reinvestment 11.8% of Rev ($21M)
90D Engineering Disclosures 0 Published

Investor FAQ IONX vs ABUS Key Questions & Quantitative Answers

As of Nov 16, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Defiance Daily Target 2X Long IONQ ETF (IONX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONX carries a Unified Composite Score of 48.8/100 (HOLD) at $8.27 (N/M Forward P/E, N/A operating margin), whereas ABUS carries 56.3/100 (HOLD) at $4.04 (10.2x Forward P/E, 80.1% operating margin). Technical & Structure Timing Caution: IONX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile ABUS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABUS leads the Growth & Scale pillar: IONX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABUS at -43.5% YoY revenue growth and +0.0% YoY earnings growth on $181M TTM revenue (91.9% gross margin, 80.1% operating margin). On trailing 12-month operating scale, IONX generates N/A in USD-normalized revenue versus $181M for ABUS. In operating R&D and SG&A reinvestment, IONX deploys N/A (0 90-day corporate R&D disclosures) versus 11.8% of Rev ($21M) (0 disclosures) for ABUS.

ABUS screens cheaper on headline valuation multiples. IONX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABUS trades at 10.2x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONX (N/A ROE) versus ABUS (269.6% ROE) capital efficiency.

In options market volatility and institutional positioning, IONX carries 181.8% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (6.79β · 232% Vol realized risk). By comparison, ABUS carries 72.9% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.20β · 51% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.